NCT03297359 2024-01-23
WAVe
Ottawa Hospital Research Institute
Phase 2 Terminated
Clinical Trials
10 trialsNCT00028678 2023-06-18
Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00952380 2019-04-16
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Pfizer
Phase 2 Completed
NCT00041782 2018-10-31
Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01817257 2018-10-29
ALICAT
Cardiff University
Phase 2 Terminated
NCT01518465 2017-11-29
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
University of Southern California
Phase 2 Terminated
NCT00216866 2017-08-28
The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Completed
NCT00323011 2014-05-21
FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
University of Southern California
Phase 2 Terminated
NCT00462852 2013-08-12
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00239980 2010-02-03
Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)
Ontario Clinical Oncology Group (OCOG)
Phase 2 Completed